Current EpiPen Patent Status
The EpiPen auto-injector was originally developed by Mylan and earlier by Merck. Key formulation and device patents have expired over time. Some device-related patents expired in the late 2010s, while newer patents have been challenged in court.
Generic and Authorized Versions
Generic epinephrine auto-injectors have entered the U.S. market as older patents lapsed. Authorized generics and competitors now offer alternatives at lower prices. The availability of these versions is tied to specific patent expirations and regulatory approvals.
Why Patent Dates Matter for Pricing
When a patent expires, other manufacturers can launch generic versions, which often reduces the price. The EpiPen market has seen price competition after key patents ended. For the latest patent details, see the U.S. Patent and Trademark Office at https://www.uspto.gov.
